Table of Contents
Epidemiology.Insulin resistance and systematic atherosclerosis (G. Howard
et al.). The Diabetes Intervention Study: impact of quality of risk factor control on coronary heart disease and mortality (M. Hanefeld, S. Fischer). Glucose, insulin and atherosclerosis: Lesson from the Bruneck Study (E. Bonora et al.). The plurimetabolic syndrome in the European population: the experience of the European Group on Insulin Resistance (EGIR) (S. Del Prato, A. Maran, H. Beck-Nielsen). Genetics. Result of 10-years genetic studies in French families with type 2 diabetes (P. Froguel). ACE genotype and diabetic nephropathy (M. Marre). Apolipoprotein E. gene polymorphism, vascular complications and nephropathy in NIDDM (C. Gabelli et al.). The atherogenic dyslipidemia of visceral obesity: need for preventive endocrinology (J.-P. Després). Molecular and Cellular Markers of Insulin Resistance and Diabetic Complications. Nitric oxide and arginine (P. Vallance). Protein kinase C activation and the formation of diabetic vascular complications (G.L. King, H. Wakasaki). Molecular basis of insulin receptor activation, signal transduction and signalling specificity (P.A. Holst, P. De Meyts). Regulation of metabolic gene expression by glucose (J. Girard, F. Foufelle, P. Ferre). Insulin Resistance, Endothelium and Diabetic Complications. Endothelium and diabetes. Evidences for a relationship between metabolic control and inappropriate nitric oxide production (A. Avogaro et al.). Effect of different lipoprotein fractions on nitric oxide and superoxide production in endothelial cells (L. Vergnani et al.). Renal Complications. Diabetic nephropathy in IDDM and NIDDM: functional studies (R. Mangili). Diabetic nephropathy in Type 1 and Type 2 diabetes: structural studies (A. Saller et al.). Cellular markers for diabetic nephropathy (R. Trevisan et al.). Atherosclerotic Complications. Dyslipidemia in diabetes: clinical importance of lipoprotein heterogeneity (M.-R. Taskinen, R. Malmström, C.J. Packard). Heterogeneity of triglyceride-rich lipoproteins in the postprandial state (F. Karpe). The role of glycation in diabetic complications (A. Lapolla, P. Traldi, D. Fedele). Oxidative stress and diabetic complications (A. Ceriello). Triglycerides increase the biosynthesis of plasminogen activator inhibitor type I: focus on their mechanism of action (E. Tremoli et al.). Altered fatty acid partitioning by PPAR activators improves glucose homeostatis; a case of PPAR&agr; and &ggr; coagonists (J. Auwerx). Prevention of Complications. The role of antihypertensive treatment in CHD prevention (L. Argenziano et al.). Antihypertensive therapy and cardiovascular complications (Ph. Passa). Pharmacologic inhibition of the renin-angiotensin system and diabetic nephropathy (G. Deferrari et al.). Calcium channel blockers and incipient diabetic nephropathy (M. Dalla Vestra et al.). Prevention of diabetic complications. Diet and cardiovascular disease: the epidemiological evidence (A. Bonanome, A. Pagnan). Effects of dietary fat and carbohydrate on insulin resistance (G. Riccardi, G. Annuzzi). Secondary prevention of coronary heart disease in diabetes: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) (K. Pyörälä). HMG-CoA reductase inhibitors in atherosclerosis (B.M. Buckley). Diabetes and atherosclerosis: a lipoprotein perspective (G. Steiner). Metformin (D. Giugliano). Metformin and the treatment of insulin resistance syndrome - The BIGPRO Studies (M.A. Charles, E. Eschwège, BIGPRO Study Group). Mechanism of action of thiazozidinediones in type 2 diabetes (K.Levin, H. Beck-Nielsen). Leptin: a perspective for the weight control problem (M. Maffei). Carnitine system and insulin resistance (G. Peluso et al.).
Index of authors.